- Home
- HSPO vs FBIO Comparison
HSPO vs FBIO Comparison
Compare HSPO & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- FBIO
- Stock Information
- Founded
- HSPO 2014
- FBIO 2006
- Country
- HSPO United States
- FBIO United States
- Employees
- HSPO N/A
- FBIO N/A
- Industry
- HSPO Blank Checks
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- FBIO Health Care
- Exchange
- HSPO Nasdaq
- FBIO Nasdaq
- Market Cap
- HSPO 49.4M
- FBIO 44.0M
- IPO Year
- HSPO 2022
- FBIO N/A
- Fundamental
- Price
- HSPO $11.99
- FBIO $1.53
- Analyst Decision
- HSPO
- FBIO Strong Buy
- Analyst Count
- HSPO 0
- FBIO 3
- Target Price
- HSPO N/A
- FBIO $21.00
- AVG Volume (30 Days)
- HSPO 2.5K
- FBIO 247.1K
- Earning Date
- HSPO 01-01-0001
- FBIO 05-14-2025
- Dividend Yield
- HSPO N/A
- FBIO N/A
- EPS Growth
- HSPO N/A
- FBIO N/A
- EPS
- HSPO 0.27
- FBIO N/A
- Revenue
- HSPO N/A
- FBIO $57,675,000.00
- Revenue This Year
- HSPO N/A
- FBIO $63.20
- Revenue Next Year
- HSPO N/A
- FBIO $66.70
- P/E Ratio
- HSPO $45.10
- FBIO N/A
- Revenue Growth
- HSPO N/A
- FBIO N/A
- 52 Week Low
- HSPO $10.87
- FBIO $1.33
- 52 Week High
- HSPO $12.41
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- HSPO 59.93
- FBIO 46.68
- Support Level
- HSPO $11.79
- FBIO $1.45
- Resistance Level
- HSPO $12.11
- FBIO $1.64
- Average True Range (ATR)
- HSPO 0.02
- FBIO 0.13
- MACD
- HSPO -0.00
- FBIO 0.00
- Stochastic Oscillator
- HSPO 65.67
- FBIO 64.52
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.